Lv54
990 积分 2024-04-24 加入
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
22天前
已完结
ntraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108
22天前
已完结
Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors
1个月前
已完结
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Reply
2个月前
已完结
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma
2个月前
已完结
Second Primary Cancer After Chimeric Antigen Receptor-T-Cell Therapy: A Review
2个月前
已完结
Malignancies after chimeric antigen receptor T-cell therapy
2个月前
已完结
Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China
2个月前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
2个月前
已完结
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
2个月前
已完结
皖公网安备34019202002308
